Trey Thoelcke - Editor for 24/7 Wall St.
Lastest Stories by Trey Thoelcke
Clorox has rewarded shareholders again with a quarterly dividend. As a Dividend Aristocrat, it is the epitome of a steady and reliable stock.
Published:
Warren Buffett recently boosted his stake in the newly independent Sirius XM. Biotech initial public offerings in the past week also prompted some huge insider buying.
Published:
Procter & Gamble has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and reliable stock.
Published:
While Nvidia stock looks like it may have plateaued, here are three less exciting stocks that could be worth more than it by 2030.
Published:
Here is a look at why companies split their stocks and why stock splits matter. Plus, upcoming stock splits to watch from Mangoceuticals, Pineapple Energy, 23andMe, and more.
Published:
Developments between Nvidia and major customer Meta this year bode well for both companies and their stocks. But is Wall Street on board?
Published:
Insider buying slowed ahead of the third-quarter earnings reporting season, but an IPO tempted one insider, and a repeat buyer returned to boost a stake.
Published:
These five candidates to be the best-performing growth stock over the next five years include biotech, energy, and software stocks.
Published:
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Published:
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
Published:
These five little-known perks to shopping at Home Depot can help consumers get more out of their shopping trips in this time of economic uncertainty.
Published:
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Published:
Apple was the first U.S. company valued at $1 trillion, then $3 trillion, but will it be first to have a $5 trillion market cap?
Published:
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Published:
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Published: